恩威医药 (301331.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(恩威医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年第三季度2023年第二季度2023年第一季度2022年第四季度2022年第三季度2022年第二季度2022年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市前上市前
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 174,636,712.20194,447,972.09200,800,387.47208,329,308.77148,462,781.23177,177,308.10157,604,605.75
 营业收入(元) 174,636,712.20194,447,972.09200,800,387.47208,329,308.77148,462,781.23177,177,308.10157,604,605.75
二、营业总成本(元) 164,905,296.50164,331,174.61168,140,196.62185,891,510.24143,388,860.28157,151,519.34134,049,118.32
 营业成本(元) 89,017,282.5398,385,290.0494,153,241.2896,837,056.9285,208,511.3886,927,976.1675,455,024.84
 研发费用(元) 6,898,509.635,940,068.552,127,675.843,045,410.962,464,401.151,060,394.92946,766.85
 营业税金及附加(元) 2,313,734.282,521,960.682,764,536.661,123,271.632,756,636.463,292,412.672,717,007.35
 销售费用(元) 54,636,944.6745,715,433.1459,019,548.4565,553,059.9339,324,690.7852,333,715.0843,296,237.94
 管理费用(元) 13,780,810.3713,550,605.9111,951,249.5120,260,454.0213,910,012.2713,631,736.0811,675,119.90
 财务费用(元) -1,741,984.98-1,782,183.71-1,876,055.12-927,743.22-275,391.76-94,715.57-41,038.56
  其中:利息收入(元) 1,762,786.481,828,860.911,936,297.59980,696.66226,500.14112,095.2578,423.97
 资产减值损失(元) 132,205.5117,166.68-39,381.0486,713.21293,570.25-124,906.70-217,804.64
 信用减值损失(元) -381,499.32-530,271.54-682,514.46316,799.86-524,120.95-717,594.33-761,692.42
三、其他经营收益
 加:投资收益(元) 817,950.06993,361.751,065,912.13694,097.99-17,844.28--
  其中:对联营企业和合营企业的投资收益(元) 7,554.70--37,014.41-17,844.28--
 资产处置收益(元) ---41,203.90----
 其他收益(元) 573,262.379,265,872.881,174,435.231,155,373.338,150,217.992,002,855.20552,831.15
四、营业利润(元) 10,873,334.3239,862,927.2534,137,438.8124,690,782.9212,975,743.9621,100,365.2823,128,821.52
 加:营业外收入(元) 266,455.66-10,073.578,611.01-371,997.9428,242.12
 减:营业外支出(元) 503.32--14,453.94423,067.182,955.361,690.53
五、利润总额(元) 11,139,286.6639,844,837.8134,147,512.3824,684,939.9912,552,676.7821,469,407.8623,155,373.11
 减:所得税费用(元) 2,166,338.473,552,425.656,477,882.626,336,040.032,287,435.412,540,496.332,897,149.60
六、净利润(元) 8,972,948.1936,292,412.1627,669,629.7618,348,899.9610,265,241.3718,928,911.5320,258,223.51
(一)按经营持续性分类
  持续经营净利润(元) 8,972,948.1936,292,412.1627,669,629.7618,348,899.9610,265,241.3718,928,911.5320,258,223.51
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 8,972,948.1936,292,412.1627,669,629.7618,348,899.9610,265,241.3718,928,911.5320,258,223.51
 扣除非经常性损益后的净利润(元) 7,596,555.5027,590,374.3325,793,201.9516,828,995.333,698,145.6116,915,900.0019,766,400.00
七、每股收益
 一、基本每股收益(元) 0.130.520.390.250.200.360.39
 二、稀释每股收益(元) 0.130.520.390.250.200.360.39
九、综合收益总额(元) 8,972,948.1936,292,412.1627,669,629.7618,348,899.9610,265,241.3718,928,911.5320,258,223.51
 归属于母公司所有者的综合收益总额(元) 8,972,948.1936,292,412.1627,669,629.7618,348,899.9610,265,241.3718,928,911.5320,258,223.51
公告日期 2023-10-272023-08-282023-04-222023-04-222022-10-272022-09-022023-04-22
审计意见(境内) 标准无保留意见

前瞻产业研究院